Castle Biosciences research finds patient demand for molecular testing in atopic dermatitis treatment

Castle Biosciences research finds patient demand for molecular testing in atopic dermatitis treatment
Castle Biosciences study on atopic dermatitis

Castle Biosciences has announced the publication of a new study examining the experiences of patients with atopic dermatitis in achieving their treatment goals.

The study reveals that patients show significant interest in the use of molecular testing to help guide the selection of systemic therapies for the condition. This development highlights ongoing efforts within the company to address treatment challenges through research initiatives focused on precision medicine.

Earlier this year, Castle Biosciences published a multi-center study validating the accuracy of its DecisionDx-SCC test for high-risk squamous cell carcinoma patients. The company also expanded its operations by opening a new laboratory and office facility in Scottsdale, Arizona. These developments mark ongoing growth and research activity at the company.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.